A NEW NON-STEROID TREATMENT FOR UVEITIS

4115 OLE-OPTH-OA-2008-2(4)-Anglade.pdf

Uveitis is an inflammatory autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently available therapies are burdened with toxicities and/or lack definitive evidence of efficacy. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile and a wide therapeutic window. If successful, voclosporin will become the first Food and Drug Administration-approved corticosteroid-sparing agent for this condition.

Comments

Popular posts from this blog

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS

RINSING YOUR CONTACT LENS CASE IS NOT ENOUGH